Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
, Gu X
, Zhang Q
Full Text Sources
To investigate the cost-effectiveness of osimertinib for the treatment of advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) T790M mutation after the failure of first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy.
PMID: 29101057 [PubMed - as supplied by publisher]